Waldenström macroglobulinaemia
Haematology · 2021–2022
2decisions
1medicine
2carried consumer input
29individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| zanubrutinib Treatment of adult patients with Waldenström macroglobulinaemia (WM) who are either treatment-naïve and unsuitable for chemo-immunotherapy (defined by CIRS… | Mar 2022 | Recommended with restriction | 14 individuals Lymphoma Foundation · Leukaemia Foundation · Rare Cancers Australia |
| zanubrutinib Treatment of Waldenström macroglobulinaemia in two populations: (i) treatment-naïve patients unsuitable for chemo-immunotherapy and (ii) relapsed/refractory… | Jul 2021 | Not recommended | 15 individuals Lymphoma Foundation · Leukaemia Foundation · Rare Cancers Australia |
Who spoke
Lymphoma Foundation · Leukaemia Foundation · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.